Guardant Health, Inc. (GH) — Analyst outlook / Analyst consensus target is. Based on 30 analyst ratings, the consensus is bullish — 28 Buy, 1 Hold, 1 Sell.
The consensus price target is $134.21 (low: $110.00, high: $175.00), representing an upside of 55.3% from the current price $86.40.
Analysts estimate Earnings Per Share (EPS) of $-3.41 and revenue of $0.73B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.56 vs est $-3.41 (missed -4.3%). 2025: actual $-3.32 vs est $-3.08 (missed -7.7%). Analyst accuracy: 94%.
GH Stock — 12-Month Price Forecast
$134.21
▲ +55.34% Upside
Average Price Target
Based on 30 Wall Street analysts offering 12-month price targets for Guardant Health, Inc., the average price target is $134.21, with a high forecast of $175.00, and a low forecast of $110.00.
The average price target represents a +55.34% change from the last price of $86.40.
Highest Price Target
$175.00
Average Price Target
$134.21
Lowest Price Target
$110.00
GH Analyst Ratings
Buy
Based on 30 analysts giving stock ratings to Guardant Health, Inc. in the past 3 months
EPS Estimates — GH
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.56
vs Est –$3.41
▼ 4.1% off
2025
Actual –$3.32
vs Est –$3.08
▼ 7.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — GH
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.739B
vs Est $0.729B
▲ 1.4% off
2025
Actual $0.982B
vs Est $0.973B
▲ 0.9% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
